文献速递垂体与肾上腺疾病

静默型促肾上腺皮质激素腺瘤原发治疗后的复发:系统综述与荟萃分析

Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2018-12-21

该系统综述与荟萃分析评估静默型促肾上腺皮质激素腺瘤(SCAs)原发治疗后的复发率,并比较其与其他非功能性垂体腺瘤(NFPAs)亚型的复发率比。纳入14项研究(297例)显示SCAs复发率为5.96/100人年,平均随访≥5年时31%复发;10项研究比较未发现SCAs与其他NFPAs亚型复发风险显著差异。

要点

  • SCAs原发治疗后复发率为5.96/100人年,平均随访≥5年累积复发率31%。
  • 手术与手术+放疗后复发率分别为5.41与4.88/100人年。
  • SCAs与其他NFPAs亚型复发率比无显著差异(RRR 1.44,95%CI 0.9-2.33,p=0.130)。

核心结论

  • 基于平均随访≥5年的研究,31%的SCAs出现复发。
  • 未发现证据支持SCAs较其他NFPAs亚型复发风险更高。

研究设计与样本

  • 系统综述与荟萃分析,检索截至2017年10月31日发表的SCAs结局文献。
  • 复发率分析纳入14项低偏倚风险研究、共297例患者。
  • 复发率比分析纳入10项中等偏倚风险研究、共244例SCAs与1622例NFPAs。

主要发现

  • SCAs复发率为5.96/100人年(95%CI 4.3-7.84)。
  • 平均随访<5年与≥5年的研究累积复发率分别为25%(95%CI 0.13-0.38)与31%(95%CI 0.23-0.40)。
  • 手术后与手术+放疗后复发率分别为5.41/100人年(95%CI 3.28-7.96)与4.88/100人年(95%CI 0.67-11.54)。
  • SCAs与其他NFPAs亚型复发率比无显著差异(RRR 1.44,95%CI 0.9-2.33,p=0.130)。
  • 仅手术治疗者比较亦无显著差异(RRR 1.17,95%CI 0.79-1.75,p=0.429)。

临床怎么用

  • SCAs术后应按高风险腺瘤进行随访,尤其平均随访≥5年时复发累积约31%。
  • 现有证据不支持将SCAs的复发风险估计得高于其他NFPAs亚型。

局限性

  • 复发率分析纳入研究为低偏倚风险,但复发率比分析纳入研究为中等偏倚风险。
  • 文献检索截止2017年10月31日。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: 2017 WHO Classification of Pituitary Tumors grades silent corticotroph adenomas (SCAs) as "high-risk adenomas" due to their aggressive clinical behavior (high probability of recurrence). However, studies comparing recurrence rates of SCAs with other non-functioning pituitary adenoma (NFPAs) subtypes have provided conflicting results. OBJECTIVE: Estimate recurrence rates of SCAs after primary treatment (surgery±radiotherapy) and recurrence rate ratios (RRR) between SCAs and other NFPA subtypes. METHODS: Systematic review of published literature reporting on outcomes of SCAs up to October 31, 2017 was conducted. Recurrence rates, RRRs, 95% confidence intervals (CIs) were estimated from each study and pooled using random effects meta-analysis model. RESULTS: For determination of SCAs recurrence rates, 14 studies (low risk of bias, 297 patients) were selected; recurrence rate was 5.96 (95% CI, 4.3-7.84) per 100 person-years. Based on studies with mean follow-up <5 or ≥5 years, 25% (cumulative incidence 0.25; 95% CI, 0.13-0.38) and 31% (cumulative incidence 0.31; 95% CI, 0.23-0.40) of SCAs had recurrence, respectively. Recurrence rates after surgery or surgery+radiotherapy were 5.41 (95% CI, 3.28-7.96) and 4.88 (95% CI, 0.67-11.54) cases per 100 person-years, respectively. Analysis of 10 eligible studies (moderate risk of bias, 244 SCAs, 1622 NFPAs) showed no significant RRR (1.44; 95% CI, 0.9-2.33, p=0.130) between the groups. Focus on tumors treated solely by surgery also revealed no significant RRR (1.17; 95% CI, 0.79-1.75, p=0.429). CONCLUSIONS: Based on studies with mean follow-up ≥5 years, 31% of SCAs have recurrence. No evidence supporting higher recurrence risk of SCAs compared with other NFPA subtypes was found.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Fountas A, Lavrentaki A, Subramanian A, et al. Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2018. PMID: 30590584. doi:10.1210/jc.2018-01956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。